Tracking a new cancer Drug's Real-World impact
NCT ID NCT07393204
Summary
This study is observing how well the drug epcoritamab works for patients with a type of aggressive lymphoma (DLBCL) that has come back or hasn't responded to at least two prior treatments. It follows 150 patients in Italy who are already receiving the drug through a special access program, tracking their response and any side effects. The goal is to understand the drug's real-world effectiveness and safety outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IRCCS Ospedale San Raffaele
Milan, Italy
Conditions
Explore the condition pages connected to this study.